Studies

 

 

--------------------------------------------------------

6/08

 

Report on Indications for ENERCEL Products

 

 

by Darryl See, MD

 

--------------------------------------------------------

 

For your further information, we are posting copies of:

 

7/7/2006

 

Background and rationale: Quality of life, disease prevention and slowing of the aging process depend upon healthy cellular, immune system, hormonal and other organ function. The number of bodily systems which need to be maintained in optimal function in order to ensure the best overall health possible is large. A number of supplements, dietary changes and other treatments would be necessary for optimal health unless a strategy of diffuse organ improvement could be achieved with one intervention. To this effect, the intracellular ACE-inducer, Enercel®, was assayed for a number of markers of vigorous overall organ function.

Methods: 1) NK cell function assay

    1. Lymphocyte proliferation
    2. IGF-1 and HGH levels
    3. Anti-cancer test
    4. Cytochrome p450 assays
    5. Glutathione peroxidase
    6. Trypan blue toxicity assay to PBMC

Results: 1) Enercel® had a 255% increase in Natural Killer-function over no additive

    1. The PI was increased by Enercel® 94% over baseline
    2. IGF-1 and HGH OD were improved by 390% and 286%, respectively
    3. Anti-cancer activity was increased by 362%
    4. Seven of nine cytochrome p450 isozymes had significantly increased activity with Enercel® addition
    5. The OD of glutathione peroxidase activity was increased by 74%
    6. There was no toxicity of up to concentrations of undiluted Enercel®

 Dr. Darryl See, M.D.

___________________________________________________________

 

"ENERCEL® has an NK boosting effect about  50% higher than Hansi"

 

Dr. Darryl See, M.D. ______________________________________________

Etheric biology (READ PAGE 225, HOMEOPATHY)

W. John Martin, M.D.

________________________________________________________

1. Immunomodulatory Effects of a Homeopathic Agent
by Darryl M. See, M.D.; Jeremiah G. Tilles, M.D.; and Cesar Bertacchini, M.D.

2. A prospective randomized clinical trial on infectious diarrhea in children under 5 years of age was done in patients of the Emergency ward, at Bloom Hospital in San Salvador. Two comparable groups were studied, 59 in the control and 64 in the test group. Therapy involved 2 doses of 3 ml q 12 of Enercel® Plus by IM in the test group. Significant values were obtained at 18 to 24 hours (p = 0.027) and 48 hours post discharge (p = 0.000) in the general group and at 48 hours post-discharge (p = 0-00) in the rotavirus sub-group. No side effects were reported.

3. Clinical Trial involving ENERCEL® Nasal Spray in the treatment of recurrent allergic disease of the upper respiratory tract: A Preliminary Communique by Rafael Ruiz, M.D., FAAP (October 1999)

4. The Letter of Reference regarding the treatment of immune suppression of patients with PPS utilizing immune globulin in combination with ENERCEL®, as presented by Darryl See, M.D. Associate Clinical Professor of Medicine, Division of Infectious Diseases at University of California Irvine Medical School (October 1997)

5. The Abstract regarding "Can Wasted Muscle be Rehydrated and Functionally Enhanced?" utilizing ENERCEL®, as presented by Carlton F. Hazlewood, Ph.D. and Zsolt Kereszti, M.D. (March 1997)

6. The Clinical Study of cases of "Allergic-Origin Othorhinological Diseases", utilizing ENERCEL® performed by Gedeon O. Kereszti, M.D., Ph.D., Department of Otolaryngology & Audiology, Magyar Inre Hospital, Ajka, Hungary (December 1996)

7. The Scientific Study with the objective of determining the toxicity of ENERCEL®. in mice, utilizing ENERCEL®, performed by Darryl See, M.D. Associate Clinical Professor of Medicine, Division of Infectious Diseases at University of California Irvine Medical School (August 1995)

8. The Scientific Study with the objective of determining the toxicity of ENERCEL® in animals, utilizing ENERCEL®, performed by Carlos Botelli, M.D., Project Director, Center of Toxicological Investigations, Buenos Aires, Argentina (August 1992)

9. The Trial Study of selective aspects of the quality of life of patients with advanced pancreatic cancer, utilizing ENERCEL®, performed by Cesar Bertacchini, M.D., Instituto de Medicina Integracion, Buenos Aires, Argentina (1992)

10. The Statistical "In Vivo" Study on experimental tumors in rats, utilizing ENERCEL®, performed by Rose M. Bergoc, M.D. and Elena S. Rivera, M.D. (1992)

11. The Analysis of the Mechanisms of Action of ENERCEL® therapeutics, performed by Cesar Bertacchini, M.D., Buenos Aires, Argentina (July 1991)

12. Penn State Lecture by D.L. Hull, M.D., regarding cooperation between traditional and alternative medicine.

13. No Toxicity of ENERCEL in Mice by Darryl See, MD, Assistant Professor of Medicine Division of Infectious Diseases
University of California, Irvine